Drugs / Selgantolimod
Selgantolimod
also known as
(2R)-2-({2-AMINO-7-FLUOROPYRIDO[3,2-D]PYRIMIDIN-4-YL}AMINO)-2-METHYLHEXAN-1-OL · GS-9688 · SLGN
Small molecule targets TLR8 via activation
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05551273 | May 2023 → Oct 2025 | HIV infectious disease, hepatitis B virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04891770 | Aug 2021 → Jan 2024 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03615066 | Aug 2018 → Dec 2019 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03491553 | Apr 2018 → Mar 2019 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Selgantolimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03491553 ↗ |
| Known as | (2R)-2-({2-AMINO-7-FLUOROPYRIDO[3,2-D]PYRIMIDIN-4-YL}AMINO)-2-METHYLHEXAN-1-OL | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594258 ↗ |
| Known as | GS-9688 | “Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not...” NCT03615066 ↗ |
| Known as | SLGN | “oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks” NCT05551273 ↗ |
| Action | Activate | “Selgantolimod (GS-9688) is a Toll-like receptor 8 (TLR8) agonist” PMID 38133554 ↗ Oct 2022 |
| Modality | Small molecule | — CHEMBL4594258 ↗ |
| Route | Oral | “Tablet(s) administered orally once weekly” NCT03491553 ↗ |
| Target | TLR8 | “Selgantolimod (GS-9688) is a Toll-like receptor 8 (TLR8) agonist” PMID 38133554 ↗ Oct 2022 |